

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Inc.

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

VOLUNTARY ANNOUNCEMENT PROGRESS IN THE RECOVERY OF TRADE RECEIVABLES

This announcement is made voluntarily by China Health Group Inc. (the "Company") to provide its shareholders and potential investors with the latest progress in the Company's recovery of trade receivables.

The board of directors of the Company (the "Board") hereby discloses the following.

I. BASIC INFORMATION OF RECEIVABLES

As disclosed in the Company's "2024 Annual Report", as at 31 December 2024, the total carrying amount of the Company's receivables was RMB128 million, and relevant impairment provisions have been fully provided in accordance with accounting standards. Such amounts mainly arise from the daily business operations of the Group and are common in the industry.

II. PROGRESS OF COLLECTION EFFORTS

Since the disclosure of the "2024 Annual Report", the Company has continuously and actively promoted the recovery of amounts and adopted classified measures according to the different situations of the debtors. The specific progress is as follows:

(A) Receivables from Related Parties

The arbitration claim filed by the Company against the connected party, Wante Pharmaceutical (Hainan) Co., Ltd., in respect of the trade receivables has been fully rejected. The Company has engaged lawyers to submit an application to set aside the arbitration award to the court with competent jurisdiction, and such application is currently under review. The Company is actively following up on the internal workflow of the court and is making its best efforts to complete the filing with the Hainan First Foreign-Related Civil and Commercial Tribunal within June 2026.

(B) Receivables from Non-Related Parties

1. Customers with sound cooperation relationship and positive repayment willingness

The Company has reached consensus with relevant customers and achieved continuous repayment by optimising coordination processes, conducting active consultations and conducting on-site visits. From 2 March 2026 (the date of the last progress announcement on collection) to the date of this announcement, repayment communications with such customers are progressing steadily.

2. Customers with long overdue receivables or operational difficulties

The Company has, in a prudent manner, engaged professional third-party institutions to conduct evaluation and disposal, and has simultaneously initiated corresponding legal proceedings to safeguard its legitimate rights and interests.

3. Amounts with significant recovery difficulties

The Company has lawfully adopted all available legal measures, including applying for the inclusion of the relevant debtors in the list of persons subject to enforcement for breach of trust. The Company will keep a close watch on their asset status and take immediate action upon the discovery of any enforceable clues.

(C) Internal Management Optimisation

To fundamentally improve the quality of operating capital, the Company has established an "Accounts Receivable Management Committee" led by the finance department and collaborated with multiple departments, specifically responsible for collection work. The Company has also strengthened the full-process internal control from customer credit evaluation to account period management to prevent new risks.

III. SUBSEQUENT PLANS

The Company will continue to take all necessary measures in accordance with laws and regulations, including but not limited to:

continuously following up on the review progress of the application to set aside the arbitration award, and determining the next legal actions (including but not limited to filing a separate civil litigation) based on the final court ruling;

continuing negotiations with normal-operating customers to ensure repayment in accordance with the repayment plans;

promoting asset tracing and legal recovery against customers for whom full impairment has been made, including but not limited to applying for court enforcement and filing legal proceedings;

regularly reporting the progress to the Board and timely fulfilling information disclosure obligations in accordance with the Stock Exchange Rules

IV. RISK WARNING

The final recovery results of the receivables may be affected by various factors and are subject to uncertainty. The Company will closely monitor changes in relevant risks and actively take effective measures to protect the interests of the Company and its shareholders.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China Health Group Inc.
GUO Xia
Chairman

Hong Kong, 3 June 2026

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Mr. Raymond Guo; one non-executive Director, being Dr. ZHANG Li; and four independent non-executive Directors, being Dr. NI Binhui, Mr. WU Shuangsi, Dr. GUO Tong and Ms. LIU Na.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for 7 days from the date of its posting. This announcement will also be posted on the Company's website at <http://www.chgi.net>.